Vanguard Global Advisers’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$189K Sell
19,952
-8,600
-30% -$95.2K ﹤0.01% 2506
2026
Q2
$688K Buy
28,552
+4,193
+17% +$127K ﹤0.01% 1958
2026
Q1
$741K Buy
+24,359
New +$649K ﹤0.01% 1813

Other funds holding CAPR

Vanguard Global Advisers's CAPR Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Capricor Therapeutics (CAPR) stake by 30% in Q3 2026, selling an estimated $95.2K and leaving 19,952 shares worth $189K. The position accounts for ﹤0.01% of the portfolio, ranked #2506.

Vanguard Global Advisers first reported a position in CAPR in Q1 2026 and has held it in 3 quarters since. The position peaked at $741K in Q1 2026. 158 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Vanguard Global Advisers held 19,952 shares of Capricor Therapeutics worth $189K as of Q3 2026.
  • Vanguard Global Advisers sold 8,600 Capricor Therapeutics shares in Q3 2026, an estimated $95.2K.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2506 holding.
  • Vanguard Global Advisers first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Capricor Therapeutics position peaked at $741K in Q1 2026.
  • 158 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.